Pembrolizumab 25 mg/ml clinical trials

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

This study looks at treating early-stage triple-negative breast cancer. It explores whether less chemotherapy is needed for some patients, especially those with many immune cells (TILs) in their tumour. Some patients might receive fewer treatments than usual.